January 29, 2026 – Thermo Fisher Scientific Inc. reported its monetary outcomes for the fourth quarter and full 12 months ended December 31, 2025.

Highlights from the fourth quarter and full 12 months 2025

• Fourth-quarter income grew 7% to $12.21 billion.
• GAAP earnings per share (EPS) grew 9% to $5.21 within the fourth quarter.
• Fourth-quarter adjusted earnings per share grew 8% to $6.57.
• Full-year income grew 4% to $44.56 billion.
• Full-year GAAP diluted earnings per share (EPS) grew 7% to $17.74.
• Full-year adjusted earnings per share grew 5% to $22.87.
• Superior confirmed development technique by launching a spread of highly effective, progressive new merchandise by way of 2025. Highlights embrace the Thermo Scientific™ Orbitrap™ Astral™ Zoom Mass Spectrometer, Thermo Scientific™ Krios™ 5 Cryo-TEM, Thermo Scientific™ Vulcan™ Automated Lab and the laboratory-based Thermo Scientific™ 5L DynaDrive™ Single Use Bioreactor. Throughout the fourth quarter, we launched the Thermo Scientific™ Helios™ MX1 Plasma Targeted Ion Beam Scanning Electron Microscope, a totally automated semiconductor evaluation system designed to speed up time-to-data for yield and manufacturing course of management, and acquired FDA approval for the Ion Torrent™ Oncomine™ Dx Goal Take a look at as a companion diagnostic to HYRNUO™, Bayer’s focused remedy for sufferers with HER2 mutated non-small cell lung most cancers, in addition to US 510(ok) clearance for the EXENT System, a novel automated platform that aids within the analysis of a number of myeloma.

Proceed studying